👉 Over 50% of Low and Middle Income Americans Are Now Stock Owners: Here’s How It Happened 💰

👉 Aging Isn’t a Crisis: It’s Your Next 10x Opportunity 🎯

👉 3 Stock in the “Longevity Economy”: High Upside Investments 📈

👉 Stop Guessing, Start Earning: A Community of Wealth Building Investors 💸

The stock market has become accessible to everyday Americans, with over 50% of low- and middle-income households (earning $30,000–$80,000) now investing.

Most of these investors got into the market in the past 5 years, as a result of technological and industry shifts that are eliminating common barriers like high fees and broker requirements.

The COVID-19 pandemic fuelled a surge of these new investors, with as many as 46 million opening a new brokerage account as people saved their stimulus checks and had ample time at home.

For many, stocks replace unattainable homeownership during soaring prices and rates, serving as a wealth-building alternative.

The S&P 500’s decade-long rise has also drawn attention, helping lower-income Americans own pieces of companies they consume from.

New entrants tend to favour volatile individual stocks over diversified index funds or ETFs, raising risks that they are unsure how to mitigate.

But on the flip side, this increased participation could narrow the wealth gap, with the bottom 50% owning just 1% of all equities as of Q1 2025.

As we continue to navigate our current markets, there is one undeniable trend that still stands out:

The world is getting older.

By 2030, the global population aged 60 and over is projected to reach 1.4 billion, up from 1.1 billion in 2023.

By 2050, this number is expected to be 2.1 billion.

And the number of people 80 and over is expected to triple and reach 426 million by 2050.

This is a major demographic shift, that is driven largely from declining birth rates and advances in healthcare, which is fuelling what is now being called as the “longevity economy”, an industry that is focused on medical innovations and lifestyle enhancements aimed at extending lifespans.

Once valued at $25 billion in 2020 and, the “longevity economy” is projected to surpass $600 billion by the end of 2025.

For investors, this presents an opportunity to capitalize on biotech, health tech, and pharmaceutical companies pioneering solutions for age-related challenges.

This economy is based on innovations targeting the biology of aging.

Biotech firms are leading the charge with therapies that are addressing cellular deterioration and gene editing to fight back against diseases like Alzheimer’s, heart failure and metabolic disorders.

At the forefront of this is AI, which is being integrated into wearable technology to monitor and optimize health in real time.

Pharmaceuticals are developing drugs that not only treat symptoms but also potentially slowing down the aging process.

These two sectors have become intertwined, with the aging population increasing demand, only growing as the years pass.

Lets consider just the baby boomers, a generation born between 1946 and 1964, which make up about 73-76 million people in the U.S. alone, who will all be 65 or older by 2030.

This class of people also hold over 51% of household wealth as of early 2025. Despite this, more than 50% of baby boomers lack sufficient retirement savings, which is resulting in heightened demand for affordable and effective longevity solutions, creating a sound foundation for investment growth.

Because the economic impact of baby boomers is large.

Their spending on “age-related” needs is set to increase, with spending among Americans over 75 set to surge.

Consumption is projected to grow by more than 80%, representing a $700 billion increase by 2030, and over $1.3 trillion by 2035.

With this “over 60” population essentially doubling by 2050, the market continues to grow.

This demand isn’t just about living longer, it’s also about living better. And you’re in a great position to profit from it as these trends continue to accelerate.

Focuses on drugs that eliminates deteriorating cells, more specifically the ones that contribute to inflammation and age-related diseases like osteoarthritis and eye disorders.

With a market cap of ~$70M, UBX offers high-upside potential if trials succeed, though it's volatile due to its early-stage pipeline.

The stock is down ~33% YTD.

Leverages AI-driven drug discovery to target aging. Their platform analyzes biological data to identify compounds for rare diseases, many linked to aging.

Recent partnerships with big pharma like Bayer have increased their cash position, allowing further expansion.

The stock is down ~35% YTD.

Drugs like Eylea treat age-related macular degeneration, a leading cause of blindness in seniors, generating billions in revenue. The companies R&D into genetic medicines could extend further into anti-aging applications.

With a market cap of over $70 billion, it’s a more stable play of the 3.

The stock is down ~6% YTD.

Pros: explosive growth potential, with the sectors market cap expected to reach $600 billion by the end of the year. Successful breakthroughs could yield high returns, backed by increased demand from an aging global population.

Cons: high risks with clinical failures that could cut stock prices in half and quickly. Regulatory delays are very common in this industry and competition is wide. Volatility can be amplified by market sentiment and many smaller firms burn cash without seeing any returns.

Navigating these opportunities requires gaining the right insights and analysis.

That's where communities like The Profit Academy come in, a space where like-minded investors discuss emerging trends, share research on stocks, and build strategies toward financial freedom.

If you're on this same path, joining could provide the edge to turn longevity innovations into real profits.

The aging population isn’t a challenge, it’s an opportunity.

Stay informed, diversify and keep a close eye on this space as it starts to evolve.

Alex (The Dividend Dominator)
Founder and CEO of Dividend Domination Inc.
Follow me on Twitter, Instagram and LinkedIn

That’s what we’re doing inside The Profit Zone Premium. Helping you stop playing a guessing game and focus on what really matters, building wealth.

I get it. I’ve been the one who was lost too.

No idea where to start. No idea what stocks to buy or even how to value them.

Trial and error is a good teacher, but it doesn’t have to be that way.

Skip all the reckless mistakes and fast track your way to wealth with our community.

Where we teach you:

You might be lost, but you don’t have to be.

Join us for less than what you’ll spend on dinner tonight.

Our members have already made enough money this year to cover their memberships for a lifetime.

And once you have the tools, you can do it over and over again scaling your portfolio to levels you never thought were possible.

Changing the course of your financial future is just one click away.